Friday, January 13, 2023 10:08:43 PM
Where is the science
To all that is going on
What is science
Or
Does that really matter
To all that is going on
What is science
Or
Does that really matter
Recent MRNA News
- Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting • ACCESS Newswire • 06/01/2026 12:00:00 PM
- Moderna Joins Global Initiative to Advance Vaccine Candidate for Bundibugyo Ebola Virus (MRNA) • IH Market News • 06/01/2026 10:38:14 AM
- Moderna and CEPI Expand Strategic Collaboration to Advance Potential Vaccine Against Bundibugyo Ebolavirus • ACCESS Newswire • 06/01/2026 09:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/29/2026 09:13:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/29/2026 09:10:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/29/2026 09:04:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/18/2026 08:57:37 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/15/2026 01:47:23 PM
- Moderna Recognized by TIME as One of the World's Most Impactful Companies • ACCESS Newswire • 05/12/2026 09:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Moderna (MRNA) Shares Surge After U.S. Passenger Tests Positive for Hantavirus • IH Market News • 05/11/2026 10:38:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/11/2026 10:06:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/08/2026 09:06:08 PM
- Moderna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data for Its Investigational Seasonal Influenza Vaccine, mRNA-1010 • ACCESS Newswire • 05/06/2026 09:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/04/2026 09:25:09 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/01/2026 08:10:14 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/01/2026 03:44:50 PM
- Moderna Reports First Quarter 2026 Financial Results and Provides Business Updates • ACCESS Newswire • 05/01/2026 10:30:00 AM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 04/30/2026 03:30:03 PM
- Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate • ACCESS Newswire • 04/21/2026 11:01:00 PM
- Moderna Announces Data to be Presented at 2026 ASCO Annual Meeting • ACCESS Newswire • 04/21/2026 02:00:00 PM
- Moderna Receives European Commission Marketing Authorization for mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19 • ACCESS Newswire • 04/21/2026 01:40:00 PM
- Moderna to Present at Upcoming Conferences in May 2026 • ACCESS Newswire • 04/21/2026 11:00:00 AM
- Moderna to Present Phase 1/2 Data on Its Investigational Cancer Antigen Therapy mRNA-4359 as First-Line Therapy in Combination with Pembrolizumab in Locally Advanced or Metastatic Melanoma at the 2026 AACR Annual Meeting • ACCESS Newswire • 04/17/2026 07:00:00 PM


